Early and late brain metastases in EGFR wild type and EGFR mutation positive non small cell lung cancer: Implications for survival.

被引：1
|
作者：
Ho, Cheryl
Yamada, Andrew
Weber, Britta
Yuan, Ren
机构：
[1] BC Canc Agcy, Vancouver, BC, Canada
[2] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19065
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Effect of EGFR Mutation Status on Graded Prognostic Assessment for Non-Small Cell Lung Cancer and Brain Metastases
    Soon, Yu Yang
    Zheng, Huili
    Kumarakulasinghe, Nesaretnam B.
    Koh, Wee Yao
    Leong, Cheng Nang
    Pang, Brandon
    Asmat, Atasha
    Soo, Ross
    Tham, Ivan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S527 - S527
  • [32] Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR-mutant and EGFR-wild type nonsquamous non-small cell lung cancer
    Huang, Yu-Chen
    Shen, Shih-Min
    Liu, Chien-Ying
    Pavlidis, Stelios
    Wang, Chih-Liang
    Ko, How-Wen
    Chung, Fu-Tsai
    Lin, Tin-Yu
    Feng, Po-Hao
    Lee, Kang-Yun
    Guo, Yi-Ke
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    THORACIC CANCER, 2018, 9 (12) : 1648 - 1655
  • [33] Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer
    Li, Lina
    Luo, Shuimei
    Lin, Heng
    Yang, Haitao
    Chen, Huijuan
    Liao, Ziyuan
    Lin, Wanzun
    Zheng, Weili
    Xie, Xianhe
    JOURNAL OF THORACIC DISEASE, 2017, 9 (08) : 2510 - 2520
  • [34] Activity of Pemetrexed on Wild-Type and Unknown Status EGFR Genes with Brain Metastases from Non-Small Cell Lung Cancer
    Fan, Y.
    Yu, X.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2090 - S2090
  • [35] EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR
    Wang, Z.
    Wu, Y. L.
    Yang, J.
    Wang, B.
    Huang, Y.
    Zhou, Q.
    Xu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Thomas E. Stinchcombe
    Current Treatment Options in Oncology, 2016, 17
  • [37] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Stinchcombe, Thomas E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (04)
  • [38] Early Radiation Therapy Combined With EGFR-TKI Is Associated With Longer Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients With Brain Metastases
    Liu, Y.
    Deng, L.
    Zhou, X.
    Zhou, L.
    Xu, Y.
    Gong, Y.
    Wang, J.
    Lu, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E436 - E436
  • [39] Nivolumab for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Yoshida, H.
    Kim, Y. H.
    Ozasa, H.
    Nagai, H.
    Sakamori, Y.
    Tsuji, T.
    Nomizo, T.
    Funazo, T.
    Yasuda, Y.
    Hirai, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2416 - S2416
  • [40] EGFR Mutation in Non-Small Cell Lung Cancer is Influenced by EGFR Amplification and Biomarkers
    Pollen, M.
    Waterman, J. P.
    Ding, M.
    Alvarez, A.
    Boyd, M.
    Streifel, J.
    Noroberg, M. L.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2009, 11 (06): : 655 - 655
12345